RecruitingNCT06490003

Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma

Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma by Biopsy Specimens.

Sponsor

City of Hope Medical Center

Enrollment

150 participants

Start Date

Jun 1, 2004

Study Type

OBSERVATIONAL

Conditions

Esophageal Squamous Cell Carcinoma Chemotherapy Effect DNA Methylation

Summary

Esophageal cancer remains a disease with a poor prognosis. Chemotherapy is an important part of its treatment, but there are cases in which chemotherapy is ineffective. The investigators aim to develop a model to predict the response to chemotherapy by DNA methylation of preoperative biopsy specimens to identify the chemotherapy ineffective group.

Eligibility

Min Age: 20 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at tissue samples from people with esophageal squamous cell carcinoma (a cancer of the food pipe) to try to predict which patients will respond well to chemotherapy after surgery. Researchers want to find biological markers that can guide treatment decisions. **You may be eligible if...** - You have been diagnosed with esophageal squamous cell carcinoma confirmed by pathology - You are receiving or have received chemotherapy as part of your treatment - You are starting chemotherapy for the first time **You may NOT be eligible if...** - A tissue sample (biopsy) cannot be obtained before treatment - You cannot be assessed 2 months after starting chemotherapy - You have multiple different cancers Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.